Intellia Therapeutics Ownership | Who Owns Intellia Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Intellia Therapeutics Ownership Summary


Intellia Therapeutics is owned by 92.18% institutional investors, 1.21% insiders, and 6.61% retail investors. Ark investment management is the largest institutional shareholder, holding 12.41% of NTLA shares. ARK Innovation ETF is the top mutual fund, with 8.59% of its assets in Intellia Therapeutics shares.

NTLA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockIntellia Therapeutics92.18%1.21%6.61%
SectorHealthcare Stocks 88.01%8.90%3.09%
IndustryBiotech Stocks 109.70%8.77%-18.47%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ark investment management12.54M12.41%$146.17M
Blackrock funding, inc. /de10.86M10.75%$126.60M
Blackrock9.60M10.05%$214.79M
Vanguard group9.10M9.53%$203.66M
Deep track capital, lp4.80M5.03%$107.42M
State street4.36M4.57%$97.64M
Regeneron pharmaceuticals3.70M3.67%$43.18M
Nikko asset management americas2.99M2.96%$34.89M
Sumitomo mitsui trust2.99M2.96%$34.89M
Morgan stanley2.34M2.45%$52.32M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Discovery value fund561.56K6.39%$12.57M
Regeneron pharmaceuticals3.70M3.94%$43.18M
Deep track capital, lp4.80M3.21%$107.42M
Contrarius investment management1.92M2.68%$42.87M
Himension capital (singapore) pte.1.03M1.63%$23.05M
Bioimpact capital443.50K1.54%$9.93M
Ark investment management12.54M1.22%$146.17M
Orchard capital management170.01K1.15%$3.80M
Evolutionary tree capital management36.26K0.84%$811.54K
Pdt partners227.22K0.48%$5.09M

Top Buyers

HolderShares% AssetsChange
Regeneron pharmaceuticals3.70M3.94%3.70M
Blackrock funding, inc. /de10.86M0.00%1.08M
Deep track capital, lp4.80M3.21%589.22K
Contrarius investment management1.92M2.68%564.88K
Blackrock9.60M0.00%488.34K

Top Sellers

HolderShares% AssetsChange
Wellington management group llp781.77K0.00%-3.38M
Rokos capital management llp---1.14M
Chevy chase trust288.32K0.01%-522.71K
Price t rowe associates inc /md/1.24M0.00%-380.09K
Voloridge investment management452.45K0.04%-343.07K

New Positions

HolderShares% AssetsChangeValue
Regeneron pharmaceuticals3.70M3.94%3.70M$43.18M
Raymond james financial411.08K0.00%411.08K$4.79M
Norges bank240.41K0.00%240.41K$5.38M
Mirae asset global etfs234.81K0.01%234.81K$5.26M
Sphera funds management139.42K0.43%139.42K$3.12M

Sold Out

HolderChange
Dinuzzo private wealth-1.00
Jfs wealth advisors-2.00
Baldwin brothers llc/ma-4.00
Family firm-15.00
Nelson, van denburg & campbell wealth management group-17.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2024290-5.54%93,104,8603.35%921.07%150-7.41%84-4.55%
Jun 30, 20243020.67%90,028,919-0.69%941.05%1605.26%86-2.27%
Mar 31, 2024300-2.28%90,656,6016.41%941.03%152-11.11%8810.00%
Dec 31, 20233074.07%85,199,4526.57%951.18%17114.77%8019.40%
Sep 30, 2023295-1.67%79,946,7452.21%901.15%1497.97%67-11.84%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
ARK Innovation ETF8.75M8.59%28.34K
ARK Disruptive Innovation Full Composite8.62M8.47%343.37K
Vanguard Total Stock Mkt Idx Inv3.04M2.99%4.16K
ARK Genomic Revolution ETF2.97M2.91%-
ARK Genomic Revolution2.86M2.81%-212.45K
iShares Russell 2000 ETF2.76M2.71%-21.00K
SPDR® S&P Biotech ETF2.75M2.70%-26.75K
Vanguard Small Cap Index2.46M2.42%33.35K
Nikko AM ARK Disruptive Innovation A USD1.95M1.92%-45.23K
Vanguard Institutional Extnd Mkt Idx Tr1.62M1.59%95.00K

Recent Insider Transactions


DateNameRoleActivityValue
Jan 29, 2025Bhanji Muna-Sell$2.64K
Jan 03, 2025Dube Michael P VP, Chief Accounting OfficerSell$16.71K
Jan 03, 2025BASTA JAMES EVP, General CounselSell$86.16K
Jan 03, 2025Lebwohl David EVP, Chief Medical OfficerSell$116.40K
Jan 03, 2025Hicks Derek EVP, Chief Business OfficerSell$79.19K

Insider Transactions Trends


DateBuySell
2025 Q1-9
2024 Q4-1
2024 Q3-1
2024 Q2-1
2024 Q1-12

NTLA Ownership FAQ


Who Owns Intellia Therapeutics?

Intellia Therapeutics shareholders are primarily institutional investors at 92.18%, followed by 1.21% insiders and 6.61% retail investors. The average institutional ownership in Intellia Therapeutics's industry, Biotech Stocks , is 109.70%, which Intellia Therapeutics falls below.

Who owns the most shares of Intellia Therapeutics?

Intellia Therapeutics’s largest shareholders are Ark investment management (12.54M shares, 12.41%), Blackrock funding, inc. /de (10.86M shares, 10.75%), and Blackrock (9.6M shares, 10.05%). Together, they hold 33.21% of Intellia Therapeutics’s total shares outstanding.

Does Blackrock own Intellia Therapeutics?

Yes, BlackRock owns 10.05% of Intellia Therapeutics, totaling 9.6M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 214.79M$. In the last quarter, BlackRock increased its holdings by 488.34K shares, a 5.36% change.

Who is Intellia Therapeutics’s biggest shareholder by percentage of total assets invested?

Discovery value fund is Intellia Therapeutics’s biggest shareholder by percentage of total assets invested, with 6.39% of its assets in 561.56K Intellia Therapeutics shares, valued at 12.57M$.

Who is the top mutual fund holder of Intellia Therapeutics shares?

ARK Innovation ETF is the top mutual fund holder of Intellia Therapeutics shares, with 8.59% of its total shares outstanding invested in 8.75M Intellia Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools